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Abstract
Introduction Pharmacokinetic interactions between casopitant
(a substrate and weak to moderate inhibitor of CYP3A),
dexamethasone (a substrate and weak inducer of CYP3A),
and ondansetron (a mixed CYP substrate) were evaluated in
a two-part, three-period, single-sequence study in two
groups of healthy subjects.
Materials and methods Part 1: subjects received oral
casopitant (regimen A); oral dexamethasone and IV
ondansetron (regimen B); and oral casopitant, a reduced
dose of oral dexamethasone, and IV ondansetron (regimen
C). Part 2: subjects received oral casopitant (regimen D); IV
dexamethasone and oral ondansetron (regimen E); and oral
casopitant, IV dexamethasone, and oral ondansetron (reg-
imen F). Each regimen was separated by 14 days.
Results Casopitant AUC in regimen C was increased 28%
on day 1 but decreased 34% on day 3 compared to casopitant
alone in regimen A. When given with casopitant and
ondansetron in regimen C, dexamethasone AUC was 17%
lower on day 1, but similar on day 3, compared to regimen B
(representing dose-normalized increases in exposure of 39%
and 108%, respectively). Ondansetron exposure was equiv-
alent in regimens B and C. Casopitant AUC in regimen F
was similar to regimen D on days 1 and 3. Dexamethasone
AUC increased 21% when given with oral casopitant and
oral ondansetron (regimen F compared to regimen E).
Ondansetron exposure was equivalent in regimens E and F.
Conclusion When repeat-dose oral dexamethasone is to be
coadministered with oral casopitant, a reduction in dexa-
methasone dose may be considered; however, no change in
casopitant dose is required. Ondansetron exposure was not
affected by coadministration with casopitant.
Keywords Casopitant.Dexamethasone.Ondansetron.
CINV
Introduction
Chemotherapy-induced nausea and vomiting(CINV)remains
one of the most feared side effects of chemotherapy among
cancer patients [25]. Several studies have reported a gap
between healthcare providers’ awareness of CINV and the
actual incidence of CINV in patients, with most healthcare
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Failure to prevent CINV can negatively affect patient
outcome by contributing to low adherence to and with-
drawal from potentially effective chemotherapy [20, 21]
and optimal prevention of CINV in the first cycle of
chemotherapy can decrease the likelihood of CINV in
subsequent cycles [4]. Furthermore, preventing CINV
during all cycles lowers the probability of developing
anticipatory CINV, a conditioned response that occurs prior
to administration of chemotherapy [20, 23].
Emesis is an autonomic reflex controlled by multiple
neurotransmitter systems; two of the most important systems
are the serotonin/5-hydroxytryptamine receptor 3 (5-HT3)
and substance P/neurokinin-1 receptor (NK-1) systems
[13]. Blocking both the 5-HT3 and NK-1 neurotransmitter
receptors has been demonstrated to reduce CINV in patients
receiving chemotherapy [5, 17, 26]. According to guide-
lines established by the Multinational Association for
Supportive Care in Cancer, patients who will receive a
moderately emetogenic chemotherapy (MEC) regimen
should receive a 5-HT3 receptor antagonist and dexameth-
asone, while patients who will receive a MEC regimen that
includes anthracycline and cyclophosphamide or a highly
emetogenic chemotherapy (HEC) regimen should receive a
5-HT3 receptor antagonist, a corticosteroid, and an NK-1
receptor antagonist [10, 12, 22].
A three-drug antiemetic regimen including a novel NK-1
receptor antagonist, casopitant, in combination with ondanse-
tron and dexamethasone has recently demonstrated efficacy
for the prevention of CINV in phase II [2] and phase III
clinical trials [3, 8, 11, 24].
An important consideration when combining medica-
tions for therapeutic benefit is the potential for drug–drug
interactions, particularly when the medications share met-
abolic pathways. Clinical a n di nv i t r os t u d i e sh a v e
demonstrated that the major enzymes involved in the
metabolism of the NK-1 receptor antagonist casopitant are
from the CYP3A family and that casopitant (and a major
circulating metabolite) can result in weak to moderate
inhibition of CYP3A.
Dexamethasone and ondansetron are commonly employed
as part of an antiemetic regimen for the prevention of CINV.
Dexamethasone is also metabolized by CYP3A and is a weak
inducer of CYP3A after prolonged exposure or repeat-dose
administration [7, 18]. Ondansetron, much like other 5-HT3
receptor antagonists, is metabolized by several CYP enzymes,
primarily CYP1A2, CYP2D6, and CYP3A [6]. Consequently,
there is a potential for casopitant to impact the pharmacoki-
netics of dexamethasone and ondansetron, and dexameth-
asone also may impact the pharmacokinetics of casopitant.
The purpose of the current study was to evaluate the
potential pharmacokinetic interactions between casopitant,
dexamethasone, and ondansetron using three drug regimens
that may be employed for the prevention of CINV resulting
from MEC or HEC. The dose of casopitant employed in the
current study is the highest oral dose regimen currently
under clinical investigation (employed in a phase III study
examining the efficacy of casopitant for the prevention of
CINV resulting from MEC [8]) and is a 3-day oral regimen
of 150 mg on day 1, followed by 50 mg on days 2 and 3.
Phase III studies (in both the HEC and MEC settings) also
examined the efficacy of a 3-day regimen of casopitant
where the day 1 oral dose was replaced by an IV dose of
90 mg casopitant, selected to provide a similar casopitant
exposure to the 150 mg oral dose form. The results of the
current study are therefore applicable to 3-day regimens of
oral/oral or IV/oral casopitant, as well as a single-dose oral
regimen consisting of 150 mg casopitant on day 1 only.
Materials and methods
Study population
Healthy male and female subjects not undergoing chemo-
therapy, 18 to 55 years of age, with a body mass index of
≥19 to ≤37 kg/m
2 and adequate organ function were
eligible to enter the study. All females of childbearing
potential were required to use birth control from 14 days
before the first dose of study medication, throughout the
study and for 14 days after the last dose of study
medication. Exclusion criteria were designed to ensure that
subjects were in good health and not receiving concomitant
medications that may interfere with the pharmacokinetics of
study medications.
The study protocol and informed consent documents
were reviewed and approved by the institutional review
board at the Buffalo Clinical Research Center. Subjects
provided written consent prior to participation in the trial.
All investigators were required to abide by Good Clinical
Practices, International Conference on Harmonization
guidelines, Declaration of Helsinki principles, and local
laws and regulations.
Study design
This open-label, two-part, fixed-sequence study was con-
ducted at one center in the USA. Subjects were only
eligible to participate in one part of the study. Each part
consisted of three treatment periods (regimens), with at
least 14 days between each period. In part 1, which was
representative of a 3-day treatment regimen for the
prevention of CINV resulting from HEC, subjects received
oral casopitant in regimen A, oral dexamethasone and IV
ondansetron in regimen B, and oral casopitant, a reduced
1178 Support Care Cancer (2009) 17:1177–1185dose of oral dexamethasone, and IVondansetron in regimen
C (Table 1). In part 2, which was representative of a 3-day
treatment regimen that may be employed for the prevention
of CINV resulting from MEC, subjects received oral
casopitant in regimen D, IV dexamethasone and oral
ondansetron in regimen E, and oral casopitant, IV dexa-
methasone, and oral ondansetron in regimen F (Table 1).
All oral doses were taken with water after at least a 4 h fast,
and when subjects were to receive multiple study medi-
cations, all doses were taken at the same time.
Blood samples for PK analysis were collected over a
24-h period on day 1 and day 3 of each treatment period at
the following times: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 5,
8, 12, 16, and 24 h post-dose. When dexamethasone was
administered twice daily (part 1, regimen B), samples were
collected pre-dose, and 0.25, 0.5, 1, 1.5, 2, 3, 5, 8, and 12 h
after the morning and evening doses. This schedule allowed
comparison of the 24 h exposure of dexamethasone after
twice daily dosing of dexamethasone alone to that observed
after once daily dosing when combined with casopitant.
Adverse events (AEs) were reported and clinical laboratory
values, ECGs, and vital signs were assessed.
Pharmacokinetics
Plasma samples were analyzed for casopitant, dexametha-
sone, and ondansetron using validated analytical methods
based on protein precipitation, followed by HPLC/MS/MS
analysis. Using a 50 μL aliquot of human plasma the lower
limit of quantification (LLQ) for casopitant was 1.50 ng/mL
and the higher limit of quantification (HLQ) was 1,500 ng/mL;
the LLQ for dexamethasone was 1.0 ng/mL and the HLQ
was 500 ng/mL. Using a 20 μL aliquot of human plasma,
the LLQ for ondansetron was 0.5 ng/mL and the HLQ was
500 ng/mL. Quality control (QC) samples, prepared at three
different analyte concentrations and stored with study
samples, were analyzed with each batch of samples against
separately prepared calibration standards. For the analysis to
be acceptable, no more than one-third of the QC results were
to deviate from the nominal concentration by more than 15%
and at least 50% of the results from each QC concentration
should be within 15% of nominal. The applicable analytical
runs met all predefined run acceptance criteria.
Pharmacokinetic parameters were determined in parts 1
and2onbothday1and3inperiods1,2,and3usingstandard
non-compartmental methods (WinNonlin, version 4.1, Phar-
sight Corp, Mountain View CA, USA). AUC was calculated
using the linear up-log down method, with AUC(0-τ)b e i n g
calculatedfor repeat-dose studymedications [AUC(0-24)was
calculated for twice daily dexamethasone] and AUC(0-∞)
being calculated for single-dose IV ondansetron or
dexamethasone administration. Cmax, tmax, and half-life
were also determined.
Statistics
For the assessment of the interactions between casopitant,
dexamethasone, and ondansetron pharmacokinetics, log(e)-
transformed AUC and Cmax parameters were statistically
analyzed by performing an analysis of variance (ANOVA)
for each analyte (casopitant, dexamethasone, or ondanse-
tron), day (1 or 3) and part (1 or 2) separately. The ANOVA
used a mixed-effects model with subject as a random effect
and treatment as a fixed effect. For assessment of the effect
of dexamethasone and/or ondansetron on casopitant phar-
macokinetics, regimen A or D was the reference treatment
and regimen C or F was the test treatment, respectively. For
assessment of the effect of casopitant on dexamethasone
and ondansetron pharmacokinetics, regimen B or E was the
reference treatment and regimen C or F was the test
treatment, respectively. Point estimates and 90% confidence
intervals for the differences of interest were constructed
using the residual variance for each part. Point and interval
estimates were then exponentially back transformed to
Table 1 Casopitant, dexamethasone, and ondansetron dosing regimens for parts 1 and 2
Part Regimen Day 1 Days 2 and 3
1 (HEC regimen) Regimen A 150 mg oral casopitant once daily 50 mg oral casopitant once daily
Regimen B 20 mg oral dexamethasone once daily 8 mg oral dexamethasone twice daily
32 mg IV ondansetron single-dose
Regimen C 150 mg oral casopitant once daily 50 mg oral casopitant once daily
12 mg oral dexamethasone once daily 8 mg oral dexamethasone once daily
32 mg IV ondansetron single-dose
2 (MEC regimen) Regimen D 150 mg oral casopitant once daily 50 mg oral casopitant once daily
Regimen E 8 mg IV dexamethasone single-dose 8 mg oral ondansetron twice daily
8 mg oral ondansetron twice daily
Regimen F 150 mg oral casopitant once daily 50 mg oral casopitant once daily
8 mg IV dexamethasone single-dose 8 mg oral ondansetron twice daily
8 mg oral ondansetron twice daily
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interest. As comparisons of dexamethasone exposure in
regimens A and C were made with different dexamethasone
dose levels, dose-normalized comparisons were also made,
where the dose-normalized fold-change was determined by
the ratio of the two dose levels (per day) multiplied by the
point estimate.
A sufficient number of subjects were enrolled to ensure
that at least 18 evaluable subjects completed each part of
the study. Based on the within-subject coefficients of
variation for casopitant, dexamethasone, and ondansetron
AUC and Cmax observed in previous studies (34.2%
being the highest value), a sample size of 18 subjects
should result in the lower and upper bounds of the 90%
CI to be within 22% of the point estimates. This
calculation was based on a symmetric two-tailed proce-
dure on the log(e) scale and a type I error rate of 5% in
each tail.
Results
A total of 44 subjects were enrolled in the study, 23 in part
1 and 21 in part 2. The majority of subjects in part 1 were
White, while approximately half of the subjects in part 2
were African American. Demographic characteristics were
otherwise similar in parts 1 and 2 and are summarized in
Table 2. Forty subjects completed the study (four subjects
withdrew during the conduct of part 1, none due to adverse
events).
Pharmacokinetics
Part 1: highly emetogenic chemotherapy regimen
Casopitant Single-dose administration (day 1) showed that
coadministration of 150 mg oral casopitant with 12 mg oral
dexamethasone (reduced-dose dexamethasone regimen com-
pared to the standard dose of 20 mg) and 32 mg IV
ondansetron resulted in a 28% increase in mean casopitant
plasma AUC(0-τ)w h e nc o m p a r e dt oc a s o p i t a n ta d m i n i s t e r e d
alone (Table 3 and Fig. 1). After 3 days coadministration of
oral casopitant (150 mg day 1, 50 mg days 2 and 3) and the
reduced-dose regimen of oral dexamethasone (12 mg day 1,
8 mg once daily days 2 and 3), casopitant AUC(0-τ)a n d
Cmax decreased by 34% and 18%, respectively, compared to
3 days of administration of casopitant alone (Table 3).
Dexamethasone On day 1, coadministration 12 mg oral
dexamethasone and 150 mg oral casopitant and 32 mg
IV ondansetron resulted in a lower mean dexamethasone
AUC(0-τ) and Cmax, by 17% and 35%, respectively, when
compared to administration of 20 mg oral dexamethasone
Table 2 Demographic characteristics of enrolled subjects
Part 1 (n=23) Part 2 (n=21)
Age, years
Median (min−max) 27.0 (20–54) 29.0 (18–55)
Gender, n (%)
Female 7 (30) 6 (29)
Male 16 (70) 15 (71)
Weight, kg
Median (range) 78.90 (61.2–100.2) 75.30 (50.4–103.4)
BMI, kg/m
2
Median (range) 24.40 (20.0–32.3) 25.70 (20.2–32.7)
Ethnicity, n (%)
Hispanic or Latino 2 (9) 0
Not Hispanic or Latino 21 (91) 21 (100)
Race
African American/African
heritage
6 (26) 10 (48)
Asian–East Asian heritage 1 (4) 0
White–White/Caucasian/
European heritage
16 (70) 11 (52)
Table 3 Comparison of casopitant, dexamethasone, and ondansetron AUC and Cmax from parts 1 and 2
Part Analyte (regimen comparison) Day AUC Geometric mean ratio (90% CI) Cmax Geometric mean ratio (90% CI)
1 (HEC regimen) Casopitant (Reg C: Reg A) 1 1.28 (1.14, 1.44) 1.06 (0.95, 1.2)
3 0.66 (0.598, 0.73) 0.82 (0.74, 0.91)
Dexamethasone (Reg C: Reg B) 1 0.83 (0.77, 0.91) 0.65 (0.59, 0.73)
3 1.04 (0.97, 1.11) 1.37 (1.20, 1.57)
Ondansetron (Reg C: Reg B) 1 1.09 (1.02, 1.16) 0.96 (0.83, 1.11)
3N A N A
2 (MEC regimen) Casopitant (Reg F: Reg D) 1 1.16 (1.07, 1.26) 1.27 (1.16, 1.39)
3 0.92 (0.83, 1.01) 0.90 (0.81, 1.01)
Dexamethasone (Reg F: Reg E) 1 1.21 (1.14, 1.28) 0.95 (0.88, 1.04)
3N A N A
Ondansetron (Reg F: Reg E) 1 1.02 (0.94, 1.11) 0.96 (0.85, 1.08)
3 1.11 (1.06, 1.17) 1.00 (0.93, 1.08)
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normalization of the pharmacokinetic parameters showed
that casopitant increased the AUC(0-τ) of oral dexameth-
asone by 39%. After 3 days of coadministration, the 24 h
AUC resulting from 8 mg once daily oral dexamethasone
combined with 50 mg oral casopitant was similar to that
resulting from 8 mg twice daily oral dexamethasone alone,
and represented a dose-normalized increase in dexametha-
sone exposure of 108%. The mean increase in the Cmax of
8 mg oral dexamethasone on day 3 was 37%.
Ondansetron Plasma exposures of 32 mg IV ondansetron
were not affected by coadministration with casopitant
(Table 3 and Fig. 1).
Part 2: moderately emetogenic chemotherapy regimen
Casopitant Single-dose administration (day 1) showed
coadministration of a single-dose of 150 mg oral casopitant
with 8 mg IV dexamethasone and 8 mg twice daily oral
ondansetron resulted in an increase in mean plasma
casopitant AUC(0-τ) and Cmax of 16% and 27%, respec-
tively (Table 3 and Fig. 2). The exposure of 50 mg oral
casopitant was not affected by 3 days of coadministration
with 8 mg twice daily oral ondansetron.
Dexamethasone The day 1 single-dose IV AUC(0-∞)o f
dexamethasone was increased by 21% when coadministered
with 150 mg oral casopitant and 8 mg twice daily
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Fig. 1 Changes in individual casopitant (top), dexamethasone (middle), and ondansetron (bottom) AUC parameters after administration of casopitant
alone, dexamethasone + ondansetron, and casopitant + dexamethasone + ondansetron, from part 1 (HEC regimen)
Support Care Cancer (2009) 17:1177–1185 1181ondansetron, but there was no change in dexamethasone
Cmax (Table 3 and Fig. 2).
Ondansetron Theday 1andday3oral ondansetronAUC(0-τ)
and Cmax were not affected by coadministration with
casopitant (Table 3 and Fig. 2).
Safety
The most commonly reported AEs were headache and
dizziness. In part 1, subjects who received oral dexameth-
asone and IVondansetron demonstrated a virtually identical
frequency of AEs, 58% and 59%, respectively, in the
presence (regimen C) or absence (regimen B) of casopitant.
Casopitant alone (regimen A) produced an AE frequency of
17% with no headache or dizziness (Table 4).
In part 2, the frequency of subjects with AEs following
administration of casopitant plus IV dexamethasone and
oral ondansetron (regimen F) was similar to the frequency
of AEs with casopitant alone (regimen D) with 24% each
and the number of AEs following administration of IV
dexamethasone and oral ondansetron without casopitant
(regimen E) was actually numerically higher (43%) than the
other two regimens (Table 4). No statistical analyses of the
safety data were performed.
The majority of AEs were considered not related to
study medication and were considered to be mild in nature.
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Fig. 2 Changes in individual casopitant (top), dexamethasone
(middle), and ondansetron (bottom) AUC parameters after adminis-
tration of casopitant alone, dexamethasone + ondansetron, and
casopitant + dexamethasone + ondansetron, from part 2 (MEC
regimen)
1182 Support Care Cancer (2009) 17:1177–1185All AEs resolved. There were no deaths on the study. One
subject, who experienced a serious adverse event of
pulmonary embolism (considered by the investigator to be
possibly related to study medication) 2 days after complet-
ing part 1, withdrew from the study. Warfarin therapy was
instituted and the AE resolved prior to hospital discharge.
Follow-up assessments of this subject after completion of
warfarin therapy show the subject has an underlying
diagnosis of type II protein C deficiency where antigen
levels are normal but activity is decreased.
Discussion
Part 1 of this study was designed to examine the potential
pharmacokinetic interactions of the addition of casopitant
to a corticosteroid/5-HT3 receptor antagonist regimen that
w o u l db eu s e df o rt h ep r e v e n t i o no fC I N Vr e s u l t i n gf r o m
HEC [10, 19]. As data from earlier studies suggested some
potential for casopitant to increase the exposure of
coadministered oral dexamethasone, the three-drug combi-
nation of casopitant, dexamethasone, and ondansetron
utilized a reduced-dose regimen of dexamethasone, with
the objective of showing that this three-drug regimen
(regimen C) provided approximately the same dexametha-
sone exposure as a standard-dose two-drug regimen of
dexamethasone and ondansetron (regimen B). Part 1 showed
that casopitant exposure was modestly affected by coadmin-
istration with dexamethasone and ondansetron, with a 28%
increase in exposure on day 1 and a 34% decrease in
exposure on day 3. These changes in casopitant exposure
when combined with repeat-dose dexamethasone would not
be considered clinically important given the patient to patient
variability in the pharmacokinetics of CYP3A substrates,
like casopitant, where exposures can vary between subjects
by as much as 50% to 80%, or higher depending on the
substrate [14]; in addition, a 3-day regimen of casopitant
combined with repeat-dose oral dexamethasone has recently
been shown to be effective in the prevention of CINV
resulting from HEC [24].
Part 1 also demonstrated that the reduced-dose
regimen of dexamethasone (from 20 mg to 12 mg on
day 1 and from 8 mg twice daily to 8 mg once daily on
days 2 and 3) was a suitable adjustment for the
pharmacokinetic effect of casopitant on dexamethasone
exposure. Although the three-drug combination resulted
in a slightly lower dexamethasone exposure on day 1
when compared to the standard-dose two-drug regimen
(17% lower), the 24 h dexamethasone exposure on day 3
was similar to the standard regimen. These results indicate
that the 3-day regimen of oral casopitant increases dexa-
methasone by 39% on day 1 and 108% on day 3. The
exposure of 32 mg IV ondansetron was not affected by
150 mg casopitant when used in this three-drug regimen and,
therefore, no dose adjustment is necessary.
The dose regimens in part 2 were designed to evaluate
the potential pharmacokinetic interactions of the addition of
casopitant to an IV dexamethasone/oral ondansetron two-
Table 4 Adverse events reported by two or more subjects
Number of subjects (%)
Part 1 Part 2
Adverse event Regimen A
(N=23)
Regimen B
(N=22)
Regimen C
(N=19)
Regimen D
(N=21)
Regimen E
(N=21)
Regimen F
(N=21)
Headache 0 5 (22%) 1 (4%) 2 (10%) 2 (10%) 2 (10%)
Dizziness 0 6 (26%) 5 (22%) 0 0 0
Disorientation 0 2 (9%) 0 0 0 0
Dyspepsia 0 0 2 (9%) 0 0 0
Fatigue 0 2 (9%) 1 (4%) 0 0 0
Hiccups 0 2 (9%) 1 (4%) 0 0 0
Insomnia 0 2 (9%) 0 0 1 (5%) 0
Paraesthesia 0 0 0 0 2(10%) 0
Tachycardia 0 1 (4%) 2 (9%) 0 0 0
Back pain 1 (4%) 1 (4%) 1 (4%) 0 0 0
Abdominal pain (upper) 0 0 0 0 1 (5%) 1 (5%)
Diarrhea 0 0 0 1 (5%) 1 (5%) 0
Myalgia 0 1 (4%) 1 (4%) 0 0 0
Nasopharyngitis 0 0 1 (4%) 0 0 1 (5%)
Vasovagal syncope 1 (4%) 0 0 1 (5%) 0 0
Abdominal pain 0 0 0 1 (5%) 0 0
Support Care Cancer (2009) 17:1177–1185 1183drug regimen for the prevention of CINV resulting from
MEC [10, 19]. In this case, no significant drug interactions
were expected and therefore no a priori dose reductions
were used in the study.
Again, casopitant exposures were only modestly affected
by coadministration with 8 mg IV dexamethasone and 8 mg
twice daily oral ondansetron on day 1 (16% increase) and
were not affected following 3 days of coadministration with
oral ondansetron. Addition of casopitant to the two-drug
regimen of IV dexamethasone and oral ondansetron resulted
in a 21% increase in dexamethasone AUC(0-∞), but no
change in ondansetron exposure on day 1 or day 3. These
results confirm that no alteration in IV dexamethasone or
oral ondansetron dose is necessary when coadministered
with 1-day or 3-day regimens of casopitant for the
prevention of MEC and this three-drug regimen has recently
been shown to be effective in the prevention of CINV
resulting from MEC [8]. The lack of interaction between
single and repeat doses of oral casopitant and single or
repeat-doses of oral doses of the 5-HT3 antagonists
dolasetron or granisetron has also recently been shown [1]
suggesting that any of these 5-HT3 receptor antagonists
could be used in a three-drug regimen with casopitant for the
prevention of CINV.
Coadministration of repeat oral doses of casopitant with
IV ondansetron and oral dexamethasone, or with IV
dexamethasone and oral ondansetron, in healthy subjects
was generally well tolerated under the conditions of this
study. One serious adverse event of severe pulmonary
embolism occurred 2 days following completion of treat-
ment in part 1. This event was considered possibly related to
treatment with study medication(s); however, follow-up
assessments of this subject after the completion of warfarin
therapy suggest type II protein C deficiency, an important
risk factor for venous thromboembolism. It has been
recommended that the subject be followed by a hematologist
because of a need for life-long anticoagulation.
The three drug combinations of casopitant, dexametha-
sone, and ondansetron employed in the current study have
been successfully utilized in phase III clinical trials,
including study arms that tested a convenient single oral
dose of 150 mg casopitant on day 1 only and replacing the
day 1 150 mg oral dose of casopitant with a 90 mg IV
infusion of casopitant as part of a 3-day IV/oral regimen [3,
8, 11, 24]. These results demonstrate that any of these
three-dosage regimens for casopitant can be added to
existing two-drug regimens consisting of a corticosteroid
and a 5-HT3 receptor antagonist. In the case of regimens for
the prevention of CINV that include repeat-doses of oral
dexamethasone (e.g., CINV resulting from HEC), a
reduction in the dose of dexamethasone from 20 mg to
12 mg on day 1 and from 8 mg twice daily to 8 mg once
daily on days 2 and 3 may be employed to maintain a
similar dexamethasone exposure to that of the standard
two-drug regimen. If a single day 1 dose of 150 mg
casopitant is to be used for the prevention of CINV, only
the day 1 dose of dexamethasone would need to be
reduced, as no interaction of significance would be
expected to occur in the day or days after single-dose
casopitant administration (half-life of 17 h, unpublished
results). In addition, as supraproportional increases in
dexamethasone exposures with increasing dose have not
been observed [16], the observations in the current study
would be applicable to a dexamethasone dose of 20 mg,
i.e., a 40% higher exposure would be expected, and this
increase (equivalent to a dexamethasone dose of 28 mg)
may not be considered clinically relevant given the
variability in exposure of CYP3A substrates [14]. When
1- or 3-day regimens of casopitant are to be added to single-
dose IV dexamethasone and repeat-dose ondansetron for
the prevention of CINV (e.g., that resulting from MEC), no
adjustment in dexamethasone dose is required. This study
also showed that casopitant does not impact the pharmaco-
kinetics of oral or IV ondansetron.
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